<PAGE>
---------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
----------------------------
Date of Report (Date of earliest event reported) July 8, 1996
------------
HYGENICS PHARMACEUTICALS, INC.
- -------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
- -------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-22806 33-0120490
- ------------------ ----------------------------
(Commission File Number) (IRS Employer Identification No.)
26941 Cabot Road, Suite 128, Laguna Hills, California 92653
- ---------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (714) 582-7644
<PAGE>
ITEM 5. OTHER EVENTS
- ------- ------------
On July 8, 1996, all members of Hygenics Pharmaceuticals, Inc. (the
"Registrant") Board of Directors and existing officers tendered resignation from
their positions as directors of the Registrant effective as of July 1, 1996,
following the Registrant's announcement that it will be unable to renew the
officers and directors liability insurance policy, which expired on June 30,
1996. No director or officer furnished any statement of disagreement as to
policies of the Registrant, as part of such resignations.
Prior to tendering such resignations, the Board of Directors elected Dean
Bradley as sole Director, Chief Executive Officer, Secretary and Chief Financial
Officer of the Registrant. Mr. Bradley presently is not the owner of securities
of the Registrant.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: July 18, 1996 HYGENICS PHARMACEUTICALS, INC.
By: /s/ Dean Bradley
------------------------------------
Dean Bradley
Chief Executive Officer
3
